{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:58:53Z","timestamp":1794718733224,"version":"4.9.1"},"reference-count":119,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":73,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K01AA26385"],"award-info":[{"award-number":["K01AA26385"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA028506"],"award-info":[{"award-number":["R01AA028506"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA030993"],"award-info":[{"award-number":["R01AA030993"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["UT2AA031151"],"award-info":[{"award-number":["UT2AA031151"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK120689"],"award-info":[{"award-number":["R01DK120689"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK121925"],"award-info":[{"award-number":["R01DK121925"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124612"],"award-info":[{"award-number":["R01DK124612"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG072288"],"award-info":[{"award-number":["R21AG072288"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>As environmental exposomes are changing with time, so are liver diseases around the globe. Due to an increasing prevalence of overnutrition and sedentary lifestyle in the global population, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis have been increasing steadily in the past decades. Alcohol consumption is another common risk factor for liver diseases such as alcohol-associated liver disease or hepatitis. For both alcohol-associated and metabolic dysfunction-associated liver diseases, hepatocyte injuries are among the early events during the development of steatotic liver disease (SLD). Hepatic inflammation and fibrosis ensue with recurring hepatic damages owing to immune responses from multiple immune cell types, particularly neutrophils, Kupffer cells and monocyte-derived macrophages in response to damage-associated and pathogen-associated molecular patterns, and extracellular matrix production predominantly from hepatic stellate cells. Both environmental and genetic factors contribute to the SLD pathogenesis. Common environmental risk factors include obesity, type 2 diabetes mellitus, unhealthy diets, sedentary lifestyle and excessive alcohol consumption. Numerous genome-wide association studies have identified multiple genetic variants associated with key traits of SLD, including patatin-like phospholipase domain containing 3 rs738409, transmembrane 6 superfamily member 2 rs58542926, membrane bound O-acyltransferase domain containing 7 rs641738 and hydroxysteroid 17 beta-dehydrogenase 13 rs72613567. Cirrhosis and liver cancer are common late-stage developments of various chronic liver diseases; however, there are pathological differences according to disease aetiologies. Therefore, preventive and therapeutic intervention strategies should align with the underlying causal and modifiable factors. Currently, multiple therapeutics have been developed or approved for treatment of SLD, including thyroid hormone receptor \u03b2 agonists, glucagon-like peptide 1 receptor agonists and fibroblast growth factor 21 analogues. The concept of this review was motivated and inspired by the Seventh Annual Symposium of Chinese American Liver Society held in San Diego, California, USA on 13\u201314 November 2024.<\/jats:p>","DOI":"10.1136\/egastro-2025-100218","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:05:20Z","timestamp":1757675120000},"page":"e100218","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Steatotic liver disease and cancer: from pathogenesis to therapeutic targets"],"prefix":"10.1136","volume":"3","author":[{"given":"Zhihong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5452-6882","authenticated-orcid":false,"given":"Xiaocheng Charlie","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"2025091204050890000_3.3.e100218.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017"},{"key":"2025091204050890000_3.3.e100218.2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"2025091204050890000_3.3.e100218.3","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"2025091204050890000_3.3.e100218.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002"},{"key":"2025091204050890000_3.3.e100218.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6"},{"key":"2025091204050890000_3.3.e100218.6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2025091204050890000_3.3.e100218.7","first-page":"662","article-title":"Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment","volume":"20","author":"Roldan","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025091204050890000_3.3.e100218.8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/apt.17958","article-title":"Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population","volume":"59","author":"Schneider","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025091204050890000_3.3.e100218.9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176345","article-title":"Alcohol-associated liver disease","volume":"134","author":"Mackowiak","year":"2024","journal-title":"J Clin Invest"},{"key":"2025091204050890000_3.3.e100218.10","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2025091204050890000_3.3.e100218.11","doi-asserted-by":"crossref","unstructured":"Wang X , Zhang L , Dong B . Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology 2024. doi:10.1097\/HEP.0000000000000786","DOI":"10.1097\/HEP.0000000000000786"},{"key":"2025091204050890000_3.3.e100218.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"2025091204050890000_3.3.e100218.13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.290114"},{"key":"2025091204050890000_3.3.e100218.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29273"},{"key":"2025091204050890000_3.3.e100218.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1901974116"},{"key":"2025091204050890000_3.3.e100218.16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312291121","article-title":"The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3","volume":"121","author":"Das","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091204050890000_3.3.e100218.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112384","article-title":"Identification of NUV-244 as a PNPLA3 I148M degrading small molecule","volume":"28","author":"Steigemann","year":"2025","journal-title":"iScience"},{"key":"2025091204050890000_3.3.e100218.18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s42255-019-0066-3","article-title":"Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes","volume":"1","author":"Yang","year":"2019","journal-title":"Nat Metab"},{"key":"2025091204050890000_3.3.e100218.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat Commun"},{"key":"2025091204050890000_3.3.e100218.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"2025091204050890000_3.3.e100218.21","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu121"},{"key":"2025091204050890000_3.3.e100218.22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144079","article-title":"Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans","volume":"5","author":"Bor\u00e9n","year":"2020","journal-title":"JCI Insight"},{"key":"2025091204050890000_3.3.e100218.23","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20131363"},{"key":"2025091204050890000_3.3.e100218.24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.92243.3","article-title":"Membrane-bound O-acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury","volume":"12","author":"Varadharajan","year":"2024","journal-title":"Elife"},{"key":"2025091204050890000_3.3.e100218.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105544","article-title":"Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025091204050890000_3.3.e100218.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191"},{"key":"2025091204050890000_3.3.e100218.27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091204050890000_3.3.e100218.28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330110"},{"key":"2025091204050890000_3.3.e100218.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"2025091204050890000_3.3.e100218.30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.cmet.2024.04.014","article-title":"Obesity disrupts the pituitary-hepatic UPR communication leading to NAFLD progression","volume":"36","author":"Qian","year":"2024","journal-title":"Cell Metab"},{"key":"2025091204050890000_3.3.e100218.31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163018","article-title":"Hepatocyte SREBP signaling mediates clock communication within the liver","volume":"133","author":"Guan","year":"2023","journal-title":"J Clin Invest"},{"key":"2025091204050890000_3.3.e100218.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155693","article-title":"ATG14 plays a critical role in hepatic lipid droplet homeostasis","volume":"148","author":"Huang","year":"2023","journal-title":"Metabolism"},{"key":"2025091204050890000_3.3.e100218.33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1515\/mr-2024-0020","article-title":"Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases","volume":"4","author":"Wang","year":"2024","journal-title":"Med Rev (2021)"},{"key":"2025091204050890000_3.3.e100218.34","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.124.000978"},{"key":"2025091204050890000_3.3.e100218.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-023-01035-1","article-title":"Bile acid-mediated signaling in cholestatic liver diseases","volume":"13","author":"Zeng","year":"2023","journal-title":"Cell Biosci"},{"key":"2025091204050890000_3.3.e100218.36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.09.027"},{"key":"2025091204050890000_3.3.e100218.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32575-8"},{"key":"2025091204050890000_3.3.e100218.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101196","article-title":"Understanding the complex macrophage landscape in MASLD","volume":"6","author":"De Ponti","year":"2024","journal-title":"JHEP Rep"},{"key":"2025091204050890000_3.3.e100218.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101454","article-title":"Resolvin D1-mediated cellular crosstalk protects against MASH","volume":"7","author":"Navarro-Corcuera","year":"2025","journal-title":"JHEP Rep"},{"key":"2025091204050890000_3.3.e100218.40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1866","article-title":"Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation","volume":"16","author":"Zhou","year":"2024","journal-title":"Sci Transl Med"},{"key":"2025091204050890000_3.3.e100218.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00845-0"},{"key":"2025091204050890000_3.3.e100218.42","first-page":"278","article-title":"Neutrophil-Lymphocyte Ratio (NLR) Could Be Better Predictor than C-reactive Protein (CRP) for Liver Fibrosis in Non-alcoholic Steatohepatitis(NASH)","volume":"45","author":"Yilmaz","year":"2015","journal-title":"Ann Clin Lab Sci"},{"key":"2025091204050890000_3.3.e100218.43","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311861"},{"key":"2025091204050890000_3.3.e100218.44","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.29919","article-title":"Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin\u20102 and neutrophil extracellular traps","volume":"68","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"2025091204050890000_3.3.e100218.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09046-8"},{"key":"2025091204050890000_3.3.e100218.46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.7150\/ijbs.58365","article-title":"MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2025091204050890000_3.3.e100218.47","doi-asserted-by":"crossref","unstructured":"He Y , Rodrigues RM , Wang X , et al . Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223\u2013enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest 2021;131. doi:10.1172\/JCI141513","DOI":"10.1172\/JCI141513"},{"key":"2025091204050890000_3.3.e100218.48","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J Hepatol"},{"key":"2025091204050890000_3.3.e100218.49","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/HEP.0000000000000333","article-title":"Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element-binding protein-like 2","volume":"78","author":"Hong","year":"2023","journal-title":"Hepatology"},{"key":"2025091204050890000_3.3.e100218.50","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000564","article-title":"Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction","volume":"8","author":"Sun","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","article-title":"IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease","volume":"78","author":"Park","year":"2023","journal-title":"J Hepatol"},{"key":"2025091204050890000_3.3.e100218.52","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405678","article-title":"OPN\u2010Mediated Crosstalk Between Hepatocyte E4BP4 and Hepatic Stellate Cells Promotes MASH\u2010Associated Liver Fibrosis","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2025091204050890000_3.3.e100218.53","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200522R","article-title":"Sirtuin 6 protects against hepatic fibrogenesis by suppressing the YAP and TAZ function","volume":"36","author":"Chowdhury","year":"2022","journal-title":"FASEB J"},{"key":"2025091204050890000_3.3.e100218.54","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261961","article-title":"Generation and characterization of mature hepatocyte organoids for liver metabolic studies","volume":"137","author":"Liu","year":"2024","journal-title":"J Cell Sci"},{"key":"2025091204050890000_3.3.e100218.55","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8030050","article-title":"Alcohol Metabolizing Enzymes, Microsomal Ethanol Oxidizing System, Cytochrome P450 2E1, Catalase, and Aldehyde Dehydrogenase in Alcohol-Associated Liver Disease","volume":"8","author":"Jiang","year":"2020","journal-title":"Biomedicines"},{"key":"2025091204050890000_3.3.e100218.56","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s42255-024-01063-2","article-title":"Coordinated action of a gut-liver pathway drives alcohol detoxification and consumption","volume":"6","author":"Fu","year":"2024","journal-title":"Nat Metab"},{"key":"2025091204050890000_3.3.e100218.57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/hep.32115","article-title":"Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology"},{"key":"2025091204050890000_3.3.e100218.58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.014"},{"key":"2025091204050890000_3.3.e100218.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00603-3"},{"key":"2025091204050890000_3.3.e100218.60","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.31535","article-title":"Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors","volume":"73","author":"Schwantes-An","year":"2021","journal-title":"Hepatology"},{"key":"2025091204050890000_3.3.e100218.61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1213738110"},{"key":"2025091204050890000_3.3.e100218.62","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000641","article-title":"Silencing FAF2 mitigates alcohol-induced hepatic steatosis by modulating lipolysis and PCSK9 pathway","volume":"9","author":"Huda","year":"2025","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.63","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1172\/JCI124376","article-title":"Brown fat activation mitigates alcohol-induced liver steatosis and injury in mice","volume":"129","author":"Shen","year":"2019","journal-title":"J Clin Invest"},{"key":"2025091204050890000_3.3.e100218.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00904-3"},{"key":"2025091204050890000_3.3.e100218.65","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000599","article-title":"The gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage","volume":"9","author":"Shen","year":"2025","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.66","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13811","article-title":"Age-dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution","volume":"22","author":"Adjei-Mosi","year":"2023","journal-title":"Aging Cell"},{"key":"2025091204050890000_3.3.e100218.67","doi-asserted-by":"crossref","unstructured":"Ma J , Guillot A , Yang Z , et al . Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. J Clin Invest 2022;132. doi:10.1172\/JCI157780","DOI":"10.1172\/JCI157780"},{"key":"2025091204050890000_3.3.e100218.68","doi-asserted-by":"crossref","unstructured":"Guan Y , Peiffer B , Feng D , et al . IL-8+ neutrophils drive inexorable inflammation in severe alcohol-associated hepatitis. J Clin Invest 2024;134. doi:10.1172\/JCI178616","DOI":"10.1172\/JCI178616"},{"key":"2025091204050890000_3.3.e100218.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.029"},{"key":"2025091204050890000_3.3.e100218.70","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jhep.2016.06.018","article-title":"Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide","volume":"65","author":"Stein","year":"2016","journal-title":"J Hepatol"},{"key":"2025091204050890000_3.3.e100218.71","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.amjmed.2022.05.015","article-title":"Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States","volume":"135","author":"Termeie","year":"2022","journal-title":"Am J Med"},{"key":"2025091204050890000_3.3.e100218.72","doi-asserted-by":"crossref","DOI":"10.3390\/biom14040404","article-title":"Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression","volume":"14","author":"Osna","year":"2024","journal-title":"Biomolecules"},{"key":"2025091204050890000_3.3.e100218.73","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000566","article-title":"Cholestatic insult triggers alcohol-associated hepatitis in mice","volume":"8","author":"Yan","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.74","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.28233"},{"key":"2025091204050890000_3.3.e100218.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.049"},{"key":"2025091204050890000_3.3.e100218.76","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00660-3","article-title":"The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model","volume":"12","author":"Setayesh","year":"2024","journal-title":"Biomark Res"},{"key":"2025091204050890000_3.3.e100218.77","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2256"},{"key":"2025091204050890000_3.3.e100218.78","doi-asserted-by":"crossref","unstructured":"Cho J-H , Kim H-G , Huang M , et al . The Patatin-Like Phospholipase Domain-Containing 3 148M Variant Exacerbates Alcohol-Induced Liver Injury and Tumorigenesis in Mice. Am J Pathol 2025. doi:10.1016\/j.ajpath.2025.04.014","DOI":"10.1016\/j.ajpath.2025.04.014"},{"key":"2025091204050890000_3.3.e100218.79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90958-1","article-title":"Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"key":"2025091204050890000_3.3.e100218.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.04.013"},{"key":"2025091204050890000_3.3.e100218.81","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4100"},{"key":"2025091204050890000_3.3.e100218.82","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332033"},{"key":"2025091204050890000_3.3.e100218.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113875"},{"key":"2025091204050890000_3.3.e100218.84","doi-asserted-by":"crossref","first-page":"101367","DOI":"10.1016\/j.jcmgh.2024.101367","article-title":"Siglec-H-\/- Plasmacytoid Dendritic Cells Protect Against Acute Liver Injury by Suppressing IFN-\u03b3\/Th1 Response and Promoting IL-21+ CD4 T Cells","volume":"18","author":"Ahodantin","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025091204050890000_3.3.e100218.85","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200310000-00014"},{"key":"2025091204050890000_3.3.e100218.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2025091204050890000_3.3.e100218.87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"2025091204050890000_3.3.e100218.88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"2025091204050890000_3.3.e100218.89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2"},{"key":"2025091204050890000_3.3.e100218.90","doi-asserted-by":"crossref","first-page":"156043","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"key":"2025091204050890000_3.3.e100218.91","doi-asserted-by":"crossref","unstructured":"Souza M , Al-Sharif L , Antunes VLJ , et al . Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Hepatology 2025. doi:10.1097\/HEP.0000000000001254","DOI":"10.1097\/HEP.0000000000001254"},{"key":"2025091204050890000_3.3.e100218.92","doi-asserted-by":"crossref","unstructured":"Ma X , Niu M , Ni H-M , et al . Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer. Hepatology 2024. doi:10.1097\/HEP.0000000000000910","DOI":"10.1097\/HEP.0000000000000910"},{"key":"2025091204050890000_3.3.e100218.93","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000480","article-title":"Repurposing of the analgesic Neurotropin for MASLD\/MASH treatment","volume":"8","author":"Tsuchiya","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.032"},{"key":"2025091204050890000_3.3.e100218.95","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"2025091204050890000_3.3.e100218.96","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000627"},{"key":"2025091204050890000_3.3.e100218.97","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000444","article-title":"Effects of intestine-specific deletion of FGF15 on the development of fatty liver disease with vertical sleeve gastrectomy","volume":"8","author":"Chow","year":"2024","journal-title":"Hepatol Commun"},{"key":"2025091204050890000_3.3.e100218.98","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"2025091204050890000_3.3.e100218.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.03.013"},{"key":"2025091204050890000_3.3.e100218.100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J Hepatol"},{"key":"2025091204050890000_3.3.e100218.101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/a-2541-2892","article-title":"Diagnosis and Management of Early Stages of ALD","volume":"45","author":"Gratac\u00f3s-Gin\u00e8s","year":"2025","journal-title":"Semin Liver Dis"},{"key":"2025091204050890000_3.3.e100218.102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6"},{"key":"2025091204050890000_3.3.e100218.103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2025091204050890000_3.3.e100218.104","doi-asserted-by":"crossref","unstructured":"Shi MA , Pungwe P , Comer LLM , et al . Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials. Hepatology 2025. doi:10.1097\/HEP.0000000000001237","DOI":"10.1097\/HEP.0000000000001237"},{"key":"2025091204050890000_3.3.e100218.105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.17665","article-title":"Systematic review: Interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis","volume":"58","author":"Oldroyd","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025091204050890000_3.3.e100218.106","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3"},{"key":"2025091204050890000_3.3.e100218.107","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"2025091204050890000_3.3.e100218.108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"2025091204050890000_3.3.e100218.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"2025091204050890000_3.3.e100218.110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091204050890000_3.3.e100218.111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"2025091204050890000_3.3.e100218.112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7"},{"key":"2025091204050890000_3.3.e100218.113","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"2025091204050890000_3.3.e100218.114","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091204050890000_3.3.e100218.115","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"2025091204050890000_3.3.e100218.116","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091204050890000_3.3.e100218.117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00604-5"},{"key":"2025091204050890000_3.3.e100218.118","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"2025091204050890000_3.3.e100218.119","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2025-100218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:05:33Z","timestamp":1757675133000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2025-100218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/egastro-2025-100218"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2025-100218","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}